Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with primary liver cancer (hepatocellular carcinoma, or HCC) that is at an early to intermediate stage (classified as BCLC 0 to B), confirmed by pathology results.
- People whose liver cancer has come back (recurred) and who have not yet received any cancer-related treatment for it.
- People with no more than 3 tumours in the liver.
- People whose tumours are each no larger than 5 cm in size.
- People in generally good physical health, as measured by a performance score of 90 or above on the KPS scale (confirm with trial site).
- People aged between 18 and 75 years.
- People whose liver function falls within a certain range, known as Child-Pugh A, or Child-Pugh B with a score no higher than 7 (confirm with trial site).
- People whose recent blood test results meet all of the following: adequate white blood cell count, platelet count, haemoglobin level, liver enzyme levels, kidney function, blood clotting measures, protein levels, and bilirubin levels within the ranges required by the trial (confirm with trial site for specific values).
Who may not be able to join:
- People who are unwilling to attend follow-up appointments or take part in the study.
- People who have a history of any other type of cancer.
- People whose liver cancer has grown into major blood vessels, such as the portal vein or hepatic vein.
- People whose cancer has spread outside the liver or to the lymph nodes.
- People who are currently receiving systemic treatments such as targeted therapy or immunotherapy.
- People who have already received local treatments such as ablation or TACE (a procedure that blocks blood supply to tumours).
- People who have experienced any of the following in the 12 months before the study: heart attack, severe or unstable chest pain, heart bypass surgery, heart failure, stroke or mini-stroke, or a blood clot in the lungs; or people who have an ongoing heart rhythm problem of a certain severity, or an abnormal heart electrical reading beyond specified limits (confirm with trial site).
- People who have other serious physical or mental health conditions, or abnormal test results, that the trial doctors believe could increase the risks of participation or affect the study results.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xianhai Mao, Professor, Hunan Provincial People's Hospital
Phone: 86 19868000115
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Tumor-free survival rate at 36 months; Over-all survival (OS) rate at 36 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.